Roche NimbleGen, Preparing Cyto Array FDA Submission, Eyes Opportunities in Oncology Dx

Roche NimbleGen CEO Frank Pitzer said recently that the firm intends to enter the diagnostics market, where it will develop "important, valuable applications," the first of which will be in the field of cytogenetics.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.